دورية أكاديمية
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
| العنوان: | A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours |
|---|---|
| المؤلفون: | Burris, Howard A., Berlin, Jordan, Arkenau, Tobias, Cote, Gregory M., Lolkema, Martijn P., Ferrer-Playan, Jordi, Kalapur, Anup, Bolleddula, Jayaprakasam, Locatelli, Giuseppe, Goddemeier, Thomas, Gounaris, Ioannis, de Bono, Johann |
| المصدر: | Burris , H A , Berlin , J , Arkenau , T , Cote , G M , Lolkema , M P , Ferrer-Playan , J , Kalapur , A , Bolleddula , J , Locatelli , G , Goddemeier , T , Gounaris , I & de Bono , J 2024 , ' A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours ' , British Journal of Cancer , vol. 130 , no. 7 , pp. 1131-1140 . https://doi.org/10.1038/s41416-023-02436-2Test |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being |
| الوصف: | Background: Gartisertib is an oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), a key kinase of the DNA damage response. We aimed to determine the safety and tolerability of gartisertib ± carboplatin in patients with advanced solid tumours. Methods: This phase I open-label, multicenter, first-in-human study comprised four gartisertib cohorts: A (dose escalation [DE]; Q2W); A2 (DE; QD/BID); B1 (DE+carboplatin); and C (biomarker-selected patients) Results : Overall, 97 patients were enroled into cohorts A (n = 42), A2 (n = 26), B1 (n = 16) and C (n = 13). The maximum tolerated dose and recommended phase II dose (RP2D) were not declared for cohorts A or B1. In cohort A2, the RP2D for gartisertib was determined as 250 mg QD. Gartisertib was generally well-tolerated; however, unexpected increased blood bilirubin in all study cohorts precluded further DE. Investigations showed that gartisertib and its metabolite M26 inhibit UGT1A1-mediated bilirubin glucuronidation in human but not dog or rat liver microsomes. Prolonged partial response (n = 1 [cohort B1]) and stable disease >6 months (n = 3) did not appear to be associated with biomarker status. Exposure generally increased dose-dependently without accumulation. Conclusion: Gartisertib was generally well-tolerated at lower doses; however, unexpected liver toxicity prevented further DE, potentially limiting antitumour activity. Gartisertib development was subsequently discontinued. ClinicalTrials.gov: NCT02278250. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://pure.eur.nl/en/publications/b8ce9c63-fcd1-4d75-8a2c-a2e3ab21d904Test |
| DOI: | 10.1038/s41416-023-02436-2 |
| الإتاحة: | https://doi.org/10.1038/s41416-023-02436-2Test https://pure.eur.nl/en/publications/b8ce9c63-fcd1-4d75-8a2c-a2e3ab21d904Test https://pure.eur.nl/ws/files/134687658/A_phase_I_study_of_ATR_inhibitor_gartisertib_M4344_as_a_single_agent_and_in_combination_with_carboplatin_in_patients_with_advanced_solid_tumours.pdfTest http://www.scopus.com/inward/record.url?scp=85183421277&partnerID=8YFLogxKTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.2146C460 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.2146C460 1022 3 Academic Journal academicJournal 1022.14886474609 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.2146C460&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1038/s41416-023-02436-2# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Burris%2C+Howard+A%2E%22">Burris, Howard A.</searchLink><br /><searchLink fieldCode="AR" term="%22Berlin%2C+Jordan%22">Berlin, Jordan</searchLink><br /><searchLink fieldCode="AR" term="%22Arkenau%2C+Tobias%22">Arkenau, Tobias</searchLink><br /><searchLink fieldCode="AR" term="%22Cote%2C+Gregory+M%2E%22">Cote, Gregory M.</searchLink><br /><searchLink fieldCode="AR" term="%22Lolkema%2C+Martijn+P%2E%22">Lolkema, Martijn P.</searchLink><br /><searchLink fieldCode="AR" term="%22Ferrer-Playan%2C+Jordi%22">Ferrer-Playan, Jordi</searchLink><br /><searchLink fieldCode="AR" term="%22Kalapur%2C+Anup%22">Kalapur, Anup</searchLink><br /><searchLink fieldCode="AR" term="%22Bolleddula%2C+Jayaprakasam%22">Bolleddula, Jayaprakasam</searchLink><br /><searchLink fieldCode="AR" term="%22Locatelli%2C+Giuseppe%22">Locatelli, Giuseppe</searchLink><br /><searchLink fieldCode="AR" term="%22Goddemeier%2C+Thomas%22">Goddemeier, Thomas</searchLink><br /><searchLink fieldCode="AR" term="%22Gounaris%2C+Ioannis%22">Gounaris, Ioannis</searchLink><br /><searchLink fieldCode="AR" term="%22de+Bono%2C+Johann%22">de Bono, Johann</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Burris , H A , Berlin , J , Arkenau , T , Cote , G M , Lolkema , M P , Ferrer-Playan , J , Kalapur , A , Bolleddula , J , Locatelli , G , Goddemeier , T , Gounaris , I & de Bono , J 2024 , ' A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours ' , British Journal of Cancer , vol. 130 , no. 7 , pp. 1131-1140 . https://doi.org/10.1038/s41416-023-02436-2 ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2024 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22%2Fdk%2Fatira%2Fpure%2Fsustainabledevelopmentgoals%2Fgood%5Fhealth%5Fand%5Fwell%5Fbeing%22">/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being</searchLink><br /><searchLink fieldCode="DE" term="%22name=SDG+3+-+Good+Health+and+Well-being%22">name=SDG 3 - Good Health and Well-being</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background: Gartisertib is an oral inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), a key kinase of the DNA damage response. We aimed to determine the safety and tolerability of gartisertib ± carboplatin in patients with advanced solid tumours. Methods: This phase I open-label, multicenter, first-in-human study comprised four gartisertib cohorts: A (dose escalation [DE]; Q2W); A2 (DE; QD/BID); B1 (DE+carboplatin); and C (biomarker-selected patients) Results : Overall, 97 patients were enroled into cohorts A (n = 42), A2 (n = 26), B1 (n = 16) and C (n = 13). The maximum tolerated dose and recommended phase II dose (RP2D) were not declared for cohorts A or B1. In cohort A2, the RP2D for gartisertib was determined as 250 mg QD. Gartisertib was generally well-tolerated; however, unexpected increased blood bilirubin in all study cohorts precluded further DE. Investigations showed that gartisertib and its metabolite M26 inhibit UGT1A1-mediated bilirubin glucuronidation in human but not dog or rat liver microsomes. Prolonged partial response (n = 1 [cohort B1]) and stable disease >6 months (n = 3) did not appear to be associated with biomarker status. Exposure generally increased dose-dependently without accumulation. Conclusion: Gartisertib was generally well-tolerated at lower doses; however, unexpected liver toxicity prevented further DE, potentially limiting antitumour activity. Gartisertib development was subsequently discontinued. ClinicalTrials.gov: NCT02278250. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => application/pdf ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://pure.eur.nl/en/publications/b8ce9c63-fcd1-4d75-8a2c-a2e3ab21d904 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1038/s41416-023-02436-2 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1038/s41416-023-02436-2<br />https://pure.eur.nl/en/publications/b8ce9c63-fcd1-4d75-8a2c-a2e3ab21d904<br />https://pure.eur.nl/ws/files/134687658/A_phase_I_study_of_ATR_inhibitor_gartisertib_M4344_as_a_single_agent_and_in_combination_with_carboplatin_in_patients_with_advanced_solid_tumours.pdf<br />http://www.scopus.com/inward/record.url?scp=85183421277&partnerID=8YFLogxK ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => info:eu-repo/semantics/openAccess ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.2146C460 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1038/s41416-023-02436-2
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
[Type] => general
)
[1] => Array
(
[SubjectFull] => name=SDG 3 - Good Health and Well-being
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Burris, Howard A.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Berlin, Jordan
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Arkenau, Tobias
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cote, Gregory M.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lolkema, Martijn P.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ferrer-Playan, Jordi
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kalapur, Anup
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bolleddula, Jayaprakasam
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Locatelli, Giuseppe
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Goddemeier, Thomas
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gounaris, Ioannis
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => de Bono, Johann
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2024
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => $2
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |